Yan Leyfman
Apr 20, 2025, 14:56
Yan Leyfman: Promising results from CD19 CAR-NK Cell therapy trial
Yan Leyfman, Co-founder and executive director of MedNews Week, shared an article by Wen Lei et al, on LinkedIn:
“Promising Results from CD19 CAR-NK Cell Therapy Trial
A Phase 1 trial using CD19-specific CAR-NK cells (CD19-BBz) derived from cord blood showed encouraging safety and efficacy in patients with relapsed/refractory large B cell lymphoma.
Key highlights:
- Repetitive dosing in 8 patients (NCT05472558)
- No cytokine release syndrome, neurotoxicity, or GVHD
- 62.5% overall response rate at day 30
- 50% achieved complete response
- Median PFS: 9.5 months; median OS not reached
- Single-cell RNA-seq revealed response-associated molecular signatures
These results demonstrate the feasibility and safety of CAR-NK therapy, offering a promising alternative to traditional CAR-T in B cell malignancies.”
Authors: Wen Lei, Xiangmin Tong, Yi Eve Sun, Aibin Liang, Wenbin Qian et al.
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 11, 2025, 11:35
May 11, 2025, 11:29
May 11, 2025, 11:17
May 11, 2025, 11:17
May 11, 2025, 11:10
May 11, 2025, 11:04
May 11, 2025, 10:47
May 11, 2025, 10:32
May 11, 2025, 10:23